[go: up one dir, main page]

MX2019000215A - Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. - Google Patents

Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.

Info

Publication number
MX2019000215A
MX2019000215A MX2019000215A MX2019000215A MX2019000215A MX 2019000215 A MX2019000215 A MX 2019000215A MX 2019000215 A MX2019000215 A MX 2019000215A MX 2019000215 A MX2019000215 A MX 2019000215A MX 2019000215 A MX2019000215 A MX 2019000215A
Authority
MX
Mexico
Prior art keywords
methods
subject
listeria
polypeptides
expressing
Prior art date
Application number
MX2019000215A
Other languages
English (en)
Inventor
Petit Robert
PRINCIOTTA Michael
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2019000215A publication Critical patent/MX2019000215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan composiciones inmunogénicas a base de Listeria que comprenden antígenos de proteína del tumor de Wilms (WT1) y métodos para tratar y vacunar contra el cáncer e inducir una respuesta inmunitaria contra este en un sujeto. Se proporcionan también en la presente polipéptidos de fusión o polipéptidos quiméricos recombinantes que comprenden antígenos de proteína del tumor de Wilms, ácidos nucleicos que codifican dichos polipéptidos quiméricos o polipéptidos de fusión, bacterias recombinantes o cepas de Listeria que comprenden dichos polipéptidos quiméricos o polipéptidos de fusión o dichos ácidos nucleicos, y bancos de células que comprenden dichas bacterias o cepas de Listeria. Se proporcionan también en la presente métodos para generar dichos polipéptidos quiméricos o polipéptidos de fusión, dichos ácidos nucleicos, y dichas bacterias recombinantes o cepas de Listeria. Se proporcionan también composiciones inmunogénicas, composiciones farmacéuticas y vacunas que comprenden dichos polipéptidos quiméricos o polipéptidos de fusión, dichos ácidos nucleicos, y dichas bacterias recombinantes o cepas de Listeria. Se proporcionan también métodos para inducir una respuesta inmunitaria anti-WT1 en un sujeto, métodos para inducir una respuesta inmunitaria de tumores que expresan anti-WT1 o cánceres que expresan anti-WT1 en un sujeto, métodos para tratar un tumor o cáncer asociado con la WT1 en un sujeto, métodos para prevenir un tumor o cáncer asociado con la WT1 o que expresa WT1 en un sujeto, y métodos para proteger un sujeto contra un tumor o cáncer asociado con la WT1 o que expresa WT1 mediante el uso de dichos polipéptidos quiméricos recombinantes o polipéptidos de fusión, ácidos nucleicos, bacterias recombinantes o cepas de Listeria, composiciones inmunogénicas, composiciones farmacéuticas o vacunas.
MX2019000215A 2016-07-05 2017-06-30 Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. MX2019000215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358539P 2016-07-05 2016-07-05
PCT/US2017/040459 WO2018009461A1 (en) 2016-07-05 2017-06-30 Listeria-based immunogenic compositions comprising wilms tumor protein antigens and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019000215A true MX2019000215A (es) 2019-11-12

Family

ID=60913096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000215A MX2019000215A (es) 2016-07-05 2017-06-30 Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.

Country Status (8)

Country Link
US (1) US20190248856A1 (es)
EP (1) EP3481854A4 (es)
JP (1) JP2019522991A (es)
CN (1) CN109641945A (es)
AU (1) AU2017293400A1 (es)
CA (1) CA3029235A1 (es)
MX (1) MX2019000215A (es)
WO (1) WO2018009461A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2017511796A (ja) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド 多標的免疫療法を目的とするバイオマーカー
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
ES3014406T3 (en) 2017-09-19 2025-04-22 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3730153A1 (en) * 2019-04-26 2020-10-28 Medizinische Hochschule Hannover Personalized immunotherapy for treatment of cancer
CN115485385A (zh) * 2020-03-04 2022-12-16 瑞泽恩制药公司 用于使肿瘤细胞对免疫疗法敏感的方法和组合物
US11767353B2 (en) * 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2021249011A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
CA2955432A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR20190082850A (ko) * 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법

Also Published As

Publication number Publication date
CA3029235A1 (en) 2018-01-11
AU2017293400A1 (en) 2019-02-07
US20190248856A1 (en) 2019-08-15
EP3481854A4 (en) 2020-07-29
JP2019522991A (ja) 2019-08-22
CN109641945A (zh) 2019-04-16
EP3481854A1 (en) 2019-05-15
WO2018009461A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
NZ753307A (en) Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MY208114A (en) Hbv vaccines and methods treating hbv
MX2020004829A (es) Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos.
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
WO2017066706A8 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
PH12019500591A1 (en) Canine adenovirus vectors
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
MA39849A (fr) Souches de listeria utilisées comme vaccin recombinant et procédé de production
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AR110730A1 (es) Vacunas de cepas recombinantes de listeria y método para usarlas en inmunoterapia de cáncer
IN2015DN02546A (es)
WO2020065349A8 (en) Vaccines and methods
WO2016116905A9 (en) Cmv antigens and uses thereof
MX2019001136A (es) Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos.
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
ZA202003070B (en) Lassa vaccine
WO2016149643A3 (en) Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
PH12018501532A1 (en) Cancer vaccines
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy